Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
REGULATORY
Supply of Anapeine Generic to Start by Year-End: Minister
As a supply crunch continues for Sandoz’s long-acting local anesthetic Anapeine (ropivacaine) in Japan, its generic version is expected to reach the market before the end of the year, Health Minister Takamaro Fukuoka said on October 8. Anapeine has been…
To read the full story
Related Article
- Terumo Puts Brake on Supply of Anapeine Generics
November 21, 2024
- Terumo Rolls Out Anapeine Generics after Expedited Listing
November 13, 2024
- Anapeine Generics Get Expedited Listing amid Supply Crunch
November 12, 2024
- Sandoz Gives Update on Anapeine Supply after Manufacturing Change
October 30, 2024
- Local Anesthetic Supply Won’t Recover Soon Despite New Site Approval: Specialist
October 28, 2024
- Sandoz Japan Gets OK to Add New Manufacturing Site for Anapeine
October 15, 2024
- Anapeine Restriction Forcing Sandoz to Curb Supply of More Local Anesthetics
August 7, 2024
- Local Anesthetic Runs Short in Japan Due to Curbed Supply of Sandoz’ Anapeine
July 31, 2024
REGULATORY
- LDP Tax Panel OKs New 40% R&D Credit for Strategic Technologies
December 12, 2025
- Pharma Renews Call to Scrap “Spillover,” “Huge-Seller” Rules as FY2026 Talks Enter Final Stretch
December 11, 2025
- 2024 Reform Spurred New Development Activity, 20 Projects Entered Clinic: Industry Poll
December 11, 2025
- Regenerative Medicine Group Accepts Deferred Debate on Market Expansion Re-Pricing
December 11, 2025
- Wholesalers Urge Price Hikes on Sub-20-Yen Drugs as Negative Margins Mount
December 11, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…